Where does LFWD stock trade?

Lifeward Ltd. (LFWD) is listed on NASDAQ.

What sector and industry is LFWD in?

Lifeward Ltd. operates in the Health Care sector, Industrial Specialties industry.

When did Lifeward Ltd. go public?

Lifeward Ltd. (LFWD) completed its IPO in 2014.

What are analysts saying about LFWD?

Lifeward Ltd. has had 1 recent analyst action on file. The most recent action was from Laidlaw: Buy with a $1000.00 price target on 2025-02-10. Recent price targets cluster around $1000.00.

What companies are similar to LFWD?

Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare LFWD side-by-side with any of them on Quantisnow.

How can I track LFWD on Quantisnow?

Quantisnow aggregates Lifeward Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LFWD to receive live email and push alerts on every new disclosure.

LFWD

NASDAQ

Lifeward Ltd.

SectorHealth CareIndustryIndustrial SpecialtiesIPO2014

$6.89-0.40 (-5.49%)

News25/Ratings1

Price$6.89+0.75 (+12.21%)

2026-03-042026-06-05

News · 26 weeks63-36%

2025-12-142026-06-07

Mix4390d

SEC Filings15(35%)
Insider15(35%)
Other8(19%)
Earnings3(7%)
M&A1(2%)
Leadership1(2%)

Latest news

25 items

9dSEC
SEC Form SD filed by Lifeward Ltd.
SD - Lifeward Ltd. (0001607962) (Filer)
18dSEC
SEC Form S-8 filed by Lifeward Ltd.
S-8 - Lifeward Ltd. (0001607962) (Filer)
18dSEC
SEC Form 10-Q filed by Lifeward Ltd.
10-Q - Lifeward Ltd. (0001607962) (Filer)
19dINSIDER
Chief Medical Officer Rose Keith Dale was granted 15,000 units of Ordinary Shares, increasing direct ownership by 720% to 17,083 units (SEC Form 4)
4 - Lifeward Ltd. (0001607962) (Issuer)
19dINSIDER
New insider Rose Keith Dale claimed ownership of 2,083 units of Ordinary Shares (SEC Form 3)
3 - Lifeward Ltd. (0001607962) (Issuer)
20dSEC
Lifeward Ltd. filed SEC Form 8-K: Other Events
8-K - Lifeward Ltd. (0001607962) (Filer)
20dPR
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
Veteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease Promotion reflects Lifeward's continued investment in clinical innovation, evidence generation, and patient outcomes across its expanding med-tech rehabilitation and biomed technology portfolio HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of
24dSEC
SEC Form NT 10-Q filed by Lifeward Ltd.
NT 10-Q - Lifeward Ltd. (0001607962) (Filer)
24dSEC
Lifeward Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition
8-K - Lifeward Ltd. (0001607962) (Filer)
24dPR
Lifeward Reports First Quarter 2026 Financial Results
Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNE
24dINSIDER
New insider Oramed Pharmaceuticals Inc. claimed ownership of 1,250,363 units of Ordinary Shares (SEC Form 3)
3 - Lifeward Ltd. (0001607962) (Issuer)
24dSEC
SEC Form SCHEDULE 13D filed by Lifeward Ltd.
SCHEDULE 13D - Lifeward Ltd. (0001607962) (Subject)
26dSEC
SEC Form EFFECT filed by Lifeward Ltd.
EFFECT - Lifeward Ltd. (0001607962) (Filer)
28dPR
Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026. Following the news release, Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll fre
30dSEC
SEC Form DEL AM filed by Lifeward Ltd.
DEL AM - Lifeward Ltd. (0001607962) (Filer)
35dPR
Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six years Zero fractures reported across 97 German users since 2018, spanning broad patient profiles and bone health conditionsFindings reinforce safety profile and support expanded adoption of ReWalk for spinal cord injury mobility Lifeward CEO Mark Grant addressed the 53rd ASIA Annual Scientific Meeting audience with a speech regarding Lifeward and its vision for restoring full function to people living with spinal cord injuries HUDSON, Mass., and YOKNEAM ILLIT, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovativ
41dSEC
SEC Form S-3 filed by Lifeward Ltd.
S-3 - Lifeward Ltd. (0001607962) (Filer)
45dSEC
Lifeward Ltd. filed SEC Form 8-K: Leadership Update
8-K - Lifeward Ltd. (0001607962) (Filer)
55dINSIDER
SEC Form 4 filed by Sigsbee William Mark
4 - Lifeward Ltd. (0001607962) (Issuer)
55dINSIDER
SEC Form 3 filed by new insider Sigsbee William Mark
3 - Lifeward Ltd. (0001607962) (Issuer)
55dINSIDER
SEC Form 4 filed by Rozenbaum Moshe H
4 - Lifeward Ltd. (0001607962) (Issuer)
55dINSIDER
SEC Form 3 filed by new insider Rozenbaum Moshe H
3 - Lifeward Ltd. (0001607962) (Issuer)
66dSEC
SEC Form D filed by Lifeward Ltd.
D - Lifeward Ltd. (0001607962) (Filer)
69dSEC
Lifeward Ltd. filed SEC Form 8-K: Other Events
8-K - Lifeward Ltd. (0001607962) (Filer)
72dINSIDER
SEC Form 4 filed by Adar Almog
4 - Lifeward Ltd. (0001607962) (Issuer)

LFWD FAQ

6 questions

Where does LFWD stock trade?
Lifeward Ltd. (LFWD) is listed on NASDAQ.
What sector and industry is LFWD in?
Lifeward Ltd. operates in the Health Care sector, Industrial Specialties industry.
When did Lifeward Ltd. go public?
Lifeward Ltd. (LFWD) completed its IPO in 2014.
What are analysts saying about LFWD?
Lifeward Ltd. has had 1 recent analyst action on file. The most recent action was from Laidlaw: Buy with a $1000.00 price target on 2025-02-10. Recent price targets cluster around $1000.00.
What companies are similar to LFWD?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare LFWD side-by-side with any of them on Quantisnow.
How can I track LFWD on Quantisnow?
Quantisnow aggregates Lifeward Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LFWD to receive live email and push alerts on every new disclosure.